Status:
WITHDRAWN
Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Head and Neck Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This randomized clinical trial studies how well Nestle Impact Advanced Recovery works in improving surgery recovery in patients with head and neck cancer. Adding a nutritional supplement, such as Nest...
Detailed Description
PRIMARY OBJECTIVES: I. Assess the effect of perioperative use of Nestle Impact Advanced Recovery (AR) on the rate of post-operative wound complications within 30 days after major head and neck surger...
Eligibility Criteria
Inclusion
- Members of all races and ethnic groups will be included
- Patients must be diagnosed with cancer of the head and neck and must be surgical candidates
- Patients must be indicated for major head and neck surgery, defined as surgeries with an anticipated post-surgical hospital stay of 4 or more days; examples of major surgeries include, but are not limited to, total laryngectomy, large oral cavity, oropharyngeal, salivary gland, or soft tissue resections requiring free flap or major regional flap (e.g. pectoralis major flap), and large skull base procedures requiring extensive skull base reconstruction
- Patients must have cross-sectional body imaging (positron emission tomography \[PET\]-computed tomography \[CT\] or equivalent) performed within 4 weeks of study enrollment and available for review
- Patient must be willing to receive Nestle IMPACT Advance Recovery for five days prior to planned surgery as well as for 5 days after surgery
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Patients with known distant metastases or other malignancies
- Patients unable to tolerate oral intake by mouth or per enteral feeding tube
- Patients with galactosemia
- Patients who have received any investigational medication within 6 weeks of enrollment, or who are scheduled to receive an investigational drug during the course of the study
- Patients currently taking IMPACT or other immunonutrition products (arginine-containing supplements) will be excluded; other forms of nutritional supplementation, such as caloric supplementation, tube feeding, or other dietary supplements are allowed on study
- Patients currently taking anabolic steroids will be excluded; patients taking corticosteroids are allowed on study
- Psychiatric illness/social situations that would limit compliance with study requirements
- Excluded patients will be allowed to participate in the trial on an observational basis only
Key Trial Info
Start Date :
November 30 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 9 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03261180
Start Date
November 30 2017
End Date
August 9 2021
Last Update
February 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239